Browse > Article
http://dx.doi.org/10.3347/kjp.2017.55.3.337

Evaluation of Boldine Activity against Intracellular Amastigotes of Leishmania amazonensis  

Salama, Isabel Cristina (Laboratorio de Parasitos e Vetores (LAPAV), Instituto de Ciencias Biologicas e da Saude, Campus Universitario do Araguaia, Universidade Federal de Mato Grosso)
Arrais-Lima, Cristina (Laboratorio de Parasitos e Vetores (LAPAV), Instituto de Ciencias Biologicas e da Saude, Campus Universitario do Araguaia, Universidade Federal de Mato Grosso)
Arrais-Silva, Wagner Welber (Laboratorio de Parasitos e Vetores (LAPAV), Instituto de Ciencias Biologicas e da Saude, Campus Universitario do Araguaia, Universidade Federal de Mato Grosso)
Publication Information
Parasites, Hosts and Diseases / v.55, no.3, 2017 , pp. 337-340 More about this Journal
Abstract
Leishmaniasis is a neglected and endemic disease that affects poorest population mainly in developing countries. A lack of adequate and definitive chemotherapeutic agents to fight against this infection has led to the investigation of numerous compounds. The aim of this study was to investigate in vitro activity of boldine against Leishmania amazonensis murine cell infection. Boldine ((S)-2,9-dihydroxy-1,10-dimethoxy-aporphine) is an aporphine alkaloid found abundantly in the leaves/bark of boldo (Peumus boldus Molina), a widely distributed tree native to Chile. The in vitro system consisted of murine macrophage infection with amastigotes of L. amazonensis treated with different concentrations from 50 to $600{\mu}g/ml$ of boldine for 24 hr. Intracellular parasite destruction was assessed by morphological examination and boldine cytotoxicity to macrophages was tested by the MTT viability assay. When cells were treated with $100{\mu}g/ml$ of boldine the reduction of parasite infection was 81% compared with untreated cultures cells. Interestingly, boldine-treatment caused a concentration-dependent decrease of macrophage infection that culminated with 96% of reduction when cells were submitted to $600{\mu}g/ml$ of boldine. Cell cultures exposed to $100{\mu}g/ml$ of boldine and $300{\mu}g/ml$ of $Glucantime^{(R)}$ during 24 hr showed a significant reduction of 50% in parasitized cells compared with cell cultures exposed just to $Glucantime^{(R)}$. The study showed that treatment with boldine produces a better effect than treatment with the reference antimonial drug, glucantime, in L. amazonensis infected macrophage. Our results suggest that boldine is a potentially useful agent for the treatment of leishmaniasis.
Keywords
Leishmania amazonensis; anti-parasitic activity; boldo; neglected disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Tietjen I, Ntie-Kang F, Mwimanzi P, Onguene PA, Scull MA, Idowu TO, Ogundaini AO, Meva'a LM, Abegaz BM, Rice CM, Andrae-Marobela K, Brockman MA, Brumme ZL, Fedida D. Screening of the Pan-African Natural Product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. PLoS One 2015; 10: e0121099.   DOI
2 Paydar M, Kamalidehghan B, Wong YL, Wong WF, Looi CY, Mustafa MR. Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models. Drug Des Devel Ther 2014; 8: 719-733.
3 Hung J, Castillo J, Jimenez G, Hasegawa M, Rodriguez M. Spectroscopic study of antileishmanial drug incubated in the promastigotes of Leishmania mexicana. Spectrochim Acta A Mol Biomol Spectrosc 2003; 59: 3177-3183.   DOI
4 Mollataghi A, Coudiere E, Hadi AHA, Mukhtar MR, Awang K, Litaudon M, Ata A. Anti-acetylcholinesterase, anti-${\alpha}$-glucosidase, anti-leishmanial and anti-fungal activities of chemical constituents of Beilschmiedia species. Fitoterapia 2012; 83: 298-302.   DOI
5 Morello A, Lipchenca I, Cassels Bk, Speisky H, Aldunate J, Repetto Y. Trypanocidal effect of boldine and related alkaloids upon several strains of Trypanosoma cruzi. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994; 107: 367-371.   DOI
6 Moreira RRD, Carlos IZ, Vilegas W. Release of Intermediate Reactive Hydrogen Peroxide by Macrophage Cells Activated by Natural Products. Biol Pharm Bull 2001; 24: 201-204.   DOI
7 Kreitmair H. Pharmacological effects of the alkaloid of Peumus boldus molina. Pharmazie 1952; 7: 507-511.
8 Frezard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009; 14: 2317-2336.   DOI
9 Grimaldi G Jr, Tesh RB. Leishmaniasis of the New World: current concepts and implications for future research. Clin Microbiol Rev 1993; 6: 230-250.   DOI
10 Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.   DOI
11 Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-1746.   DOI
12 Kedzierski L, Curtis JM, Kedzierska K. Early $CD44hiCD^{4+}$ and $CD44hiCD^{8+}$ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity. Parasitology 2009; 136: 833-840.   DOI
13 Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004; 2: 279-292.   DOI
14 Eissa MM, Amer EI, El Sawy SM. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis. Exp Parasitol 2011; 128: 382-390.   DOI
15 Brito AM, Dos Santos D, Rodrigues SA, Brito RG, Xavier-Filho L. Plants with anti-Leishmania activity: Integrative review from 2000 to 2011. Pharmacogn Rev 2013; 7: 34-41.   DOI
16 Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008; 13: 161-171.   DOI
17 Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public health policy failure. Lancet 2002; 359: 2188-2194.   DOI
18 Trinconi CT, Reimao JQ, Yokoyama-Yasunaka JK, Miguel DC, Uliana SR. Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 2014; 58: 2608-2613.   DOI
19 O’Brien P, Carrasco-Pozo C, Speisky H. Boldine and its antioxidant or health-promoting properties. Chem Biol Interact 2006; 159: 1-17.   DOI
20 Mukhtar MR1, Aziz AN, Thomas NF, Hadi AH, Litaudon M, Awang K. Grandine A, a new proaporphine alkaloid from the bark of Phoebe grandis. Molecules 2009; 23: 1227-1233.
21 Lau YS, Tian XY, Huang Y, Murugan D, Achike FI, Mustafa MR. Boldine protects endothelial function in hyperglycemia-induced oxidative stress through an antioxidant mechanism. Biochem Pharmacol 2013; 85: 367-375.   DOI
22 Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 1990; 71: 556-559.
23 Degrossoli A, Giorgio S. Functional alterations in macrophages after hypoxia selection. Exp Biol Med 2007; 232: 88-95.
24 Barbieri CL, Giorgio S, Merjan AJ, Figueiredo EN. Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody. Infect Immun 1993; 61: 2131-2137.
25 Giorgio S, Linares E, Ischiropoulos H, Von Zuben FJ, Yamada A, Augusto O. In vivo formation of electron paramagnetic resonance-detectable nitric oxide and nitrotyrosine is not impaired during murine leishmaniasis. Infect Immun 1998; 66: 807-814.
26 Colhone MC, Arrais-Silva WW, Picoli C, Giorgio S. Effect of hypoxia on macrophage infection by Leishmania amazonensis. J Parasitol 2004; 90: 510-515.   DOI
27 Chang KP. Human cutaneous leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 1980; 209: 1240-1242.   DOI
28 Linares, E, Augusto O, Barao SC, Giorgio S. Leishmania amazonensis infection does not inhibit systemic nitric oxide levels elicited by lipopolysaccharide in vivo. J Parasitol 2000; 86: 78-82.   DOI